revenu million
valu usd unless otherwis note
upgrad op reward/risk epacadostat
view upgrad outperform sector
perform maintain target share consider
high exist products/pipelin help place floor
share believ reward/risk go epacadostat ph iii data
improv substanti see buy opportun ahead
epacadostat expect look much check stock
sept high vs believ expect
ph iii epa melanoma readout come reward/risk
equat improv substanti go data continu
believ epacadostat like show clinic meaning
benefit vs pembro alon base histor comparison
see analys here- slide though acknowledg
challeng interpret open-label data context numer
could influenc respons checkpoint inhibitor alon
believ current valuat alreadi account risk
floor valuat jakafi baricitinib cash pipelin ennanc reward/
risk remain bullish jakafi continu lt growth prospect
calcul fair valu jakafi undiscount tax cash flow
patent expiri low per share assum margin
revenu baricitinib royalti even conserv assumpt
account increas competit class safeti uncertainti
add -- especi consid eu de-risk recent
clinic regulatori progress provid partner incorpor
current net cash suggest floor share low-
even complet epacadostat failur would includ
potenti success rest inci development pipelin
given track record would like neg assumpt
potenti jakafi life cycl extens addl patent protect and/or
combo pim-i could help drive share back least
see attract buy opportun current depress level
potenti downsid risk trial failur insignific
potenti upsid epacadostat success melanoma increas
po cancer indic least calcul
plenti pipelin left long one believ
trial outcom least coin flip reward/risk
skew posit suggest buy opportun will get
front event
pleas see full stock-specif preview note
price prior trade day market close estimate unless otherwis note
bloomberg capit market estim upside/downside/target
base case assum jakafi sale exceed
 long-term driven continu growth core market
probabl success new indic gvhd
et assum epa like real
activ po late-stag tumor type
baricitinib gain approv expect
out-year prob -adjust annual revenu rest pipelin
target use dcf discount rate
late-stag success epacadostat multipl tumor type
posit phase data jakafi et gvhd approv
baricitinib reason label better-than-
expect success within earlier-stag pipelin would
provid upsid scenario base dcf analysi
would suggest fair valu
failur epacadostat indic beyond melanoma
erod price power jakafi poor perform
earlier-stag pipelin anoth fda reject baricitinib
would creat downsid scenario dcf
would suggest fair valu
long-term potenti
jakafi consider
 sale continu beat near-term sale
expect limit downsid risk commerci execut
support strong revenu foundat compani
also believ epacadostat like
activ across number differ solid tumor indic
particularli melanoma compani one
deepest cancer-focus pipelin biotech reflect
strong drug discoveri engin busi develop
expertis enabl maintain entrench
cancer space long-term overal believ
sale expect epacadostat balanc larg
market opportun even signific regulatori risk
baricitinib under-valued compani valuat
follow recent stock downsid believ foundat
compani strong see good entri point go
ph iii epacadostat melanoma studi potenti baricitinib
approv earlier-stag pipelin matur
posit high opportun jakafi driven growth
exist mf/pv indic long-term opportun
et gvhd strong price power construct partner
good commerci execut consider potenti
lead io asset epacadostat across number solid tumor
mani repres large-market opportun deep
pipelin cancer-focus asset potenti drive long-
term revenu high market opportun baricitinib
regulatori hurdl overcom drug show
efficaci indic beyond ra
space make futur price power market share
difficult draw definit conclus epa
efficaci combo studi may difficult prove fda
bari associ increas risk te event
higher dose ultim approv rest pipelin
remain early-stag catalyst meaning de-risk
asset near term
updat data on-going combo
studi phase ii data fgf-alter
tumor phase ii gvhd data jakafi
producteventtimelinejakafidata pivot ph ii acut steroid-refractori gvhd file acut gvhd accel approv acut ph studi file full approv chronic ph studi snda file chronic et trial nda add pembro ph combo studi lung bladder head/neck nivo ph combo studi lung ph durvalumab combo trial nsclc adjuvant/stag data on-going combo ph ii assess data go/no-go decis dlbcl melanoma data combo treatment-nav acut gvhd combo egfr nsclc ph i/ii dose escal advanc ongong fgf-alter studi bladder cholangio ph ii fl margin zone mantl cell cmet nv file brd-i present ph ib dose-esc advanc malign pim present ph ib dose-esc advanc malign doubletscomplet pair biopsi exhibit pipelin
drug/target partner/mechan indicationstatusjakafi nv mf pv gvhd etmarket mf pvolumi ra ad slemarket eu japan pre-registr epacadostatsolid tumorsphas iiicapmatinib nv cmet nsclcphase brd-i cancerphas carcinomaphas malignanciesphas bladder cancer cholangiocarcinoma mpnsphase sclcphase pim advanc malignanciesphas arg solid tumorsphas gitr solid tumorsphas tumorsphas iitop ruxolitinibvitiligo atop dermatitisphas mru cancerpreclinicalpipelin exhibit incom statement
incom statement thousand except share royalties- sale probability-blend net eu revenu royalti probability-adjust pipelin revenu product fair valu acq-rel conting cost incom unreal gain loss long-term debt exchang net pre-tax benefit incom incom per share outstand share outstand biotechnolog
price target base dcf discount futur cash flow annual
termin growth rate begin jakafi patent expiri price target
support outperform rate
risk rate price target
downsid risk includ failur epacadostat poor epacadostat market penetr given
crowd cancer landscap greater-than-expect slow jakafi regulatori setback
baricitinib limit efficaci signal within earlier-stag pipelin
biotechnolog compani focus develop commerci
deep pipelin intern discov small molecul drug candid oncolog
inflammatori indic lead product jakafi ruxolitinib inhibitor market
myelofibrosi mf polycythemia vera pv addit acquisit ariad eu
oper add second approv compound portfolio iclusig cml
incyt wholli own inhibitor epacadostat evalu combin therapi
multipl immune-checkpoint inhibitor solid tumor phase trial first-lin
advanc melanoma on-going within inflammatori diseas space incyt advanc
compound baricitinib jak inhibitor out-licens lilli develop
drug rheumatoid arthriti ra indic baricitinib olumi approv
ema februari approv fda drug also explor
indic atop dermat system lupu erythematosu addit
compound wholli own pipelin includ small molecul inhibitor
fgfr brd
